Back to News and Media
Dexcom ONE+ Launches in Australia to Offer Innovative Continuous Glucose Monitoring for Aussies Living with Type 2 Diabetes
- The new Dexcom ONE+ Continuous Glucose Monitoring (CGM) system is a small, all-in-one wearable that measures and sends glucose levels in real-time to a smart device* or optional receiver, with no fingerpricks†.
- Dexcom ONE+ is an easy to use CGM with essential alerts suitable for people with Type 2 diabetes
- Along with Dexcom G7, Dexcom ONE+ is Dexcom’s most accurate CGM system¶, and has the smallest sensor in Australia§ with a 30-minute sensor warmup time, the fastest of any CGM on the market||.
- More than 1.5 million Aussies live with diabetes (around 5.5% of the population) and up to 500,000 live with it undiagnosed. Over 300 Aussies develop it every day, equivalent to one person every five minutes1. It is the 21st century epidemic and the biggest challenge confronting Australia’s healthcare system.
DexCom, Inc., a global leader in glucose health for people living with diabetes, today announced that the Dexcom ONE+ continuous glucose monitoring (CGM) system is now available for people living with Type 2 diabetes in Australia.
Dexcom ONE+ is wearable technology that helps individuals to confidently manage their glucose levels by sending real-time glucose readings automatically to a compatible smart device* or optional receiver, with no fingerpricks†, leading to informed treatment decisions and better health outcomes2-6.
“We’re thrilled to offer Dexcom ONE+, a CGM solution that can support people living with Type 2 diabetes. Dexcom is committed to bringing the most up to date glucose management technology to Australians, with Dexcom ONE+ closely following the launch of the Dexcom G7 CGM in September 2024,” said Dr. Samy Saad, senior director, Dexcom Australia.
Dexcom ONE+ builds on the trusted performance of Dexcom CGM, which is clinically proven to lower HbA1c and reduce hyper- and hypoglycaemia2-6. Its customisable alerts can help users spend more time in range2-8 while industry-leading remote monitoring and reporting capabilities also allow users to stay connected with their loved ones and healthcare teams anytime, anywhere for peace of mind.#,8
Key Features of Dexcom ONE+
- Easy self-start CGM, which seamlessly integrates into a daily routine
- All-in-one wearable that is the smallest sensor (along with Dexcom G7) in Australia§
- 30-minute sensor warm up – along with Dexcom G7 is the fastest of any CGM on the market||
- 10-day sensor wear with an additional 12-hour grace period making changing sensors more convenient
- Indicated for wear on the back of the upper arm and abdomen
- Superior accuracy¶ giving users the confidence to make informed treatment decisions
- Customisable high and low alert settings suited for people living with type 2 diabetes including the unique Delay First High alert
- Real-time glucose readings sent automatically to a compatible display device*
- Remote monitoring, enabling users to share glucose data with up to 10 followers#
- Waterproof when swimming, showering, or exercising^
For further information about Dexcom ONE+ visit Dexcom.com
About DexCom, Inc.
Dexcom empowers people to take control of health through innovative biosensing technology. Founded in 1999, Dexcom has pioneered and set the standard in glucose biosensing for more than 25 years. Its technology has transformed how people manage diabetes, track their glucose and understand overall metabolic health, helping users feel more in control and live more confidently.
*Smart device sold separately. To view a list of compatible devices, visit dexcom.com/compatibility
†If your glucose alerts and readings from Dexcom ONE+ do not match symptoms or expectations, use a blood glucose meter to make diabetes treatment decisions.
‡This product is indicated for persons with diabetes mellitus age 2 years and older where self-monitoring of blood glucose (SMBG) is indicated
§Dexcom, Data on File, 2024
||Dexcom ONE+ can complete warmup within 30 minutes, whereas other CGM brands require up to an hour or longer
¶As compared to Dexcom G6 CGM
#Separate Dexcom Follow app and internet connection required. Internet connectivity required for data sharing. Users should always confirm readings on the Dexcom ONE+ app or receiver before making treatment decisions.
^The Dexcom ONE+ Sensor is waterproof and may be submerged under 2.4 metres of water for up to 24 hours without failure when properly installed.
†If your glucose alerts and readings from Dexcom ONE+ do not match symptoms or expectations, use a blood glucose meter to make diabetes treatment decisions.
‡This product is indicated for persons with diabetes mellitus age 2 years and older where self-monitoring of blood glucose (SMBG) is indicated
§Dexcom, Data on File, 2024
||Dexcom ONE+ can complete warmup within 30 minutes, whereas other CGM brands require up to an hour or longer
¶As compared to Dexcom G6 CGM
#Separate Dexcom Follow app and internet connection required. Internet connectivity required for data sharing. Users should always confirm readings on the Dexcom ONE+ app or receiver before making treatment decisions.
^The Dexcom ONE+ Sensor is waterproof and may be submerged under 2.4 metres of water for up to 24 hours without failure when properly installed.
References:
1 Diabetes Australia. Diabetes in Australia. Accessible at www.diabetesaustralia.com.au/about-diabetes/diabetes-in-australia
2 Beck, RW, et al. JAMA. 2017;317(4):371-378;
3 Beck RW, et al. Ann Intern Med. 2017;167(6):365-374;
4 Martens T, et al. JAMA. 2021;325(22):2262-2272; .
5 Laffel LM, et al. JAMA. 2020;323(23):2388-2396;3
6 Welsh JB, et al. J Diabetes Sci Technol. 2024;18(1):143-7
7 Polonsky WH, et al. Diabetes Technol Ther. 2021;23(3):195-202
8 Gilbert TR, et al. Diabetes Technol Ther. 2021;23(S1):S35-S39
1 Diabetes Australia. Diabetes in Australia. Accessible at www.diabetesaustralia.com.au/about-diabetes/diabetes-in-australia
2 Beck, RW, et al. JAMA. 2017;317(4):371-378;
3 Beck RW, et al. Ann Intern Med. 2017;167(6):365-374;
4 Martens T, et al. JAMA. 2021;325(22):2262-2272; .
5 Laffel LM, et al. JAMA. 2020;323(23):2388-2396;3
6 Welsh JB, et al. J Diabetes Sci Technol. 2024;18(1):143-7
7 Polonsky WH, et al. Diabetes Technol Ther. 2021;23(3):195-202
8 Gilbert TR, et al. Diabetes Technol Ther. 2021;23(S1):S35-S39